Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where David N. Johnston is active.

Publication


Featured researches published by David N. Johnston.


Bioorganic & Medicinal Chemistry Letters | 2000

Pyrrolo[2,3-d]pyrimidines containing an extended 5-substituent as potent and selective inhibitors of lck I

Lee D. Arnold; David J. Calderwood; Richard W. Dixon; David N. Johnston; Joanne S Kamens; Rainer Munschauer; Paul Rafferty; Sheldon Ratnofsky

Pyrrolo[2,3-d]pyrimidines containing a 5-(4-phenoxyphenyl) substituent are potent and selective inhibitors of Ick in vitro; some compounds are selective for lck over src. Data are shown for two compounds demonstrating that they are potent and selective inhibitors of IL2 production in cells.


Bioorganic & Medicinal Chemistry Letters | 2002

Pyrrolo[2,3-d]pyrimidines containing diverse N-7 substituents as potent inhibitors of Lck.

David J. Calderwood; David N. Johnston; Rainer Munschauer; Paul Rafferty

A series of pyrrolo[2,3-d]pyrimidines was synthesized and evaluated as inhibitors of Lck. Lck accommodates a diverse set of substituents at N-7. Altering the substituent at N-7 provided compound 13, an orally available lck inhibitor which inhibited TCR mediated IL-2 production after oral dosing.


Archive | 1999

4-aminopyrrolopyrimidines as kinase inhibitors

David J. Calderwood; Lee D. Arnold; Hormoz Mazdiyasni; Gavin C. Hirst; Bojuan B. Deng; David N. Johnston; Paul Rafferty; Gerald Bernard Tometzki; Helen L. Twigger; Rainer Munschauer


Archive | 1998

Pyrrolo 2,3d]pyrimidines and their use as tyrosine kinase inhibitors

David J. Calderwood; David N. Johnston; Paul Rafferty; Helen L. Twigger; Rainer Munschauer; Lee D. Arnold


Archive | 2000

Pyrrolopyrimidines as therapeutic agents

Gavin C. Hirst; David J. Calderwood; Rainer Munschauer; Lee D. Arnold; David N. Johnston; Paul Rafferty


Archive | 2000

Pyrrolopyrimidines as tyrosine kinase inhibitors

Gavin C. Hirst; David J. Calderwood; Rainer Munschauer; Lee D. Arnold; David N. Johnston; Paul Rafferty


Archive | 1998

Substituted 4-amino-7H-pyrrolo [2,3,-d]-pyrimidines as PTK inhibitors

David J. Calderwood; David N. Johnston; Paul Rafferty; Helen L. Twigger; Rainer Munschauer; Lee D. Arnold


Archive | 1986

Arylcyclobutylalkyl amines and their use as antidepressive medicines

John Rosindale Housley; James Edward Jeffery; David N. Johnston; Bruce Jeremy Sargent


Archive | 1994

Isoquinoline derivatives as therapeutic agents

Bruce Jeremy Sargent; David N. Johnston; Andrew Philip Austin Crew


Archive | 1990

Arylcyclobutylmethylamine therapeutic agents

John Rosindale Housley; James Edward Jeffery; David N. Johnston; Bruce Jeremy Sargent

Collaboration


Dive into the David N. Johnston's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Paul Rafferty

University of Nottingham

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge